Pharmaceutical

GT Biopharma announced four patients have enrolled in the company’s trial of their cancer therapy OXS-1550.

 GT Biopharma (OTCQB:OXIS) announced four patients have enrolled in the company’s trial of their cancer therapy OXS-1550.
As quoted in the press release:

Oxis Biotech, a wholly owned subsidiary of GT Biopharma, owns the worldwide rights to commercialize OXS-1550. The targeted immuno-oncology company is focused on novel antibody constructs that provide alternative treatments to cancer patients for whom existing therapies have failed.
The Phase 2 clinical trial is being conducted with Oxis’ partner, the University of Minnesota’s Masonic Cancer Center. Earlier this year, researchers at the University of Minnesota completed a Phase 1 trial of OXS-1550 to determine the safe and effective dose of the drug. The Phase 2 portion of the trial began in April and a total of 12 patients are expected to participate. Results of the Phase 2 trial are expected to be released in the first quarter of 2018.

Click here to read the full press release.

Source: www.accesswire.com

Featured

MARKETS

Markets
TSX20181.92+80.54
TSXV705.58+14.41
DOW31253.13-236.94
S&P 5003900.79-22.89
NASD11388.50-29.66
ASX7064.50-118.20

COMMODITIES

Commodities
Gold1844.78+2.60
Silver22.02+0.12
Copper4.32+0.03
Palladium2004.50+0.50
Platinum967.00+8.00
Oil112.45+0.24
Heating Oil3.68+0.02
Natural Gas7.96-0.35

DOWNLOAD FREE REPORTS

×